COX-2/sEH双抑制剂PTUPB通过抑制内质网应激改善小鼠非酒精性脂肪性肝病

doi:10.13418/j.issn.1001-165x.2020.05.014

中国临床解剖学杂志 ›› 2020, Vol. 38 ›› Issue (5): 562-567.doi: 10.13418/j.issn.1001-165x.2020.05.014

COX-2/sEH双抑制剂PTUPB通过抑制内质网应激改善小鼠非酒精性脂肪性肝病

张君¹，　张晨宇²，　孙晨晨²，　田清¹，杨慧慧²，刘昱镳²，杨金桐²，周勇²，刘绍坤³

1. 湖南医药学院医学院生理学教研室，湖南怀化 418000； 2. 中南大学基础医学院生理学系，湖南长沙 410078；
3. 中南大学湘雅二医院呼吸内科，湖南长沙 410011

收稿日期:2020-06-16 出版日期:2020-09-25 发布日期:2020-10-21
通讯作者: 刘绍坤，医学博士，副主任医师，E-mail: shaokunliu228@csu.edu.cn
作者简介:张君（1981-），湖南怀化人，硕士，副教授，E-mail: hhyzzj1314@126.com
基金资助:
湖南省教育厅科学研究项目（16A153）；湖南省自然科学基金（2019JJ40453）

COX-2/sEH dual inhibitor PTUPB alleviates non-alcoholic fatty liver disease in mice by inhibiting endoplasmic reticulum stress

ZHANG Jun¹, ZHANG Chen-yu², SUN Chen-chen², TIAN Qing¹, YANG Hui-hui², LIU Yu-biao², YANG Jin-tong², ZHOU Yong², LIU Shao-kun³

1.Department of Physiology, Medical School, Hunan University of Medicine, Huaihua 418000, Hunan Province, China; 2. Department of Physiology, Basic Medical School, Central South University, Changsha 410078, Hunan Province, China; 3. Department of Respiratory Medicine, the Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province , China

Received:2020-06-16 Online:2020-09-25 Published:2020-10-21

摘要/Abstract

摘要： 目的　探讨环氧合酶2（COX-2）和可溶性环氧化物水解酶（sEH）的双抑制剂PTUPB对非酒精性脂肪性肝病（NAFLD）小鼠肝脏的保护作用及机制。方法　将32只C57BL/6雄性小鼠随机分为对照组（Control）、双抑制剂对照组（PTUPB）、高糖高脂饲料组（HFD）和双抑制剂治疗组（HFD+PTUPB）。其中PTUPB组和HFD+PTUPB组每天皮下注射COX-2/sEH双抑制剂PTUPB（5 mg/kg），Control组和HFD组皮下注射PTUPB的溶剂PEG400。12周后，观察各组小鼠的体重变化；HE染色、油红O染色和Masson染色分别观察小鼠肝组织病理改变、脂质堆积及胶原沉积；Western blot法检测小鼠肝组织内质网应激相关蛋白IRE-1α和XBP-1s的表达；Real-time PCR检测棕榈酸（PA）处理的小鼠肝细胞（AML-12）内质网应激相关基因（Perk、Ire-1α、Xbp-1s和Aft-6）的表达。结果　与HFD组小鼠相比，HFD+PTUPB组小鼠体重及体重变化率显著降低，肝组织病理损伤、脂质堆积和胶原沉积明显改善，IRE-1α和XBP-1s的蛋白表达显著下调；进一步在细胞水平观察到，PTUPB预处理可降低PA诱导的AML-12细胞内质网相关基因的表达。结论　抑制COX-2和sEH可减轻HFD诱导的小鼠NAFLD，其机制与抑制肝细胞内质网应激有关。

关键词: PTUPB, 　非酒精性脂肪性肝病, 　内质网应激

Abstract: Objective　To investigate the protective role and mechanism of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) dual inhibitor PTUPB in non-alcoholic fatty liver disease (NALFD) in mice. Methods Thirty-two male C57BL/6 mice were randomly divided into the following groups: a control group, a PTUPB group, a HFD group, and a HFD + PTUPB group. Mice in the PTUPB group and the HFD + PTUPB group were subcutaneously injected with COX-2/sEH dual inhibitor PTUPB (5 mg/kg/d). Mice in the control group and the HFD group were subcutaneously injected with PEG400. After 12 weeks, the weight change of mice was observed. HE, Oil red O, and Masson staining were used to observe liver tissue pathology morphologic changes, lipid accumulation, and collagen deposition, respectively. The protein expression of IRE-1α and XBP-1s in the liver of NAFLD mice was detected by Western blot. The expression of genes related to endoplasmic reticulum stress (Perk，Ire-1α，Xbp-1s and Aft-6) in AML-12 treated with palmitic acid (PA) was detected by Real-time PCR. Results Compared with the HFD group, the body weight and weight change rate of mice in the HFD + PTUPB group significantly reduced. The liver pathological damage, lipid accumulation, and collagen deposition significantly ameliorated, and the protein expressions of IRE-1α and XBP-1s significantly down-regulated in the HFD + PTUPB group. In vitro, PTUPB pretreatment could reduce the expression levels of genes related to endoplasmic reticulum stress in AML-12 cells PA-induced. Conclusions Dual inhibition of COX-2 and sEH attenuates HFD-induced NALFD by suppressing endoplasmic reticulum stress in mice.

Key words: PTUPB; , , Non-alcoholic fatty liver disease; , , Endoplasmic reticulum stress

中图分类号:

R333.4

张君, 张晨宇, 孙晨晨, 田清, 杨慧慧, 刘昱镳, 杨金桐, 周勇, 刘绍坤 . COX-2/sEH双抑制剂PTUPB通过抑制内质网应激改善小鼠非酒精性脂肪性肝病[J]. 中国临床解剖学杂志, 2020, 38(5): 562-567.

ZHANG Jun, ZHANG Chen-yu, SUN Chen-chen, TIAN Qing, YANG Hui-hui, LIU Yu-biao, YANG Jin-tong, ZHOU Yong, LIU Shao-kun. COX-2/sEH dual inhibitor PTUPB alleviates non-alcoholic fatty liver disease in mice by inhibiting endoplasmic reticulum stress[J]. Chinese Journal of Clinical Anatomy, 2020, 38(5): 562-567.

参考文献 29

[1]	Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(7): 411-428.
[2]	Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention [J]. Nat Rev Gastroenterol Hepatol, 2017, 15(1): 11-20.
[3]	Hu H, Lin A, Kong M, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives [J]. J Gastroenterol, 2020, 55(2): 142-158.
[4]	Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review [J]. JAMA, 2020, 323(12): 1175-1183.
[5]	Lebeaupin C, Vallée D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease [J]. J Hepatol, 2018, 69(4): 927-947.
[6]	Kim Y, Natarajan SK, Chung S. Gamma-tocotrienol attenuates the hepatic inflammation and fibrosis by suppressing endoplasmic reticulum stress in mice [J]. Mol Nutr Food Res, 2018, 62(21): e1800519.
[7]	Han CY, Rho HS, Kim A, et al. FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury [J]. Cell Rep, 2018, 24(11): 2985-2999.
[8]	Wang T, Fu X, Chen Q, et al. Arachidonic acid metabolism and kidney inflammation [J]. Int J Mol Sci, 2019, 20(15): 3683.
[9]	Zhou Y, Liu T, Duan J-X, et al. Soluble epoxide hydrolase inhibitor attenuates lipopolysaccharide-induced acute lung injury and improves survival in mice [J]. Shock, 2017, 47(5): 638-645.
[10]	Gartung A, Yang J, Sukhatme VP, et al. Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor [J]. Proc Natl Acad Sci U S A, 2019, 116(5): 1698-1703.
[11]	Dileepan M, Rastle-Simpson S, Greenberg Y, et al. Effect of dual sEH/COX-2 inhibition on allergen-induced airway inflammation [J]. Front Pharmacol, 2019, 10: 1118.
[12]	Zhang CY, Duan JX, Yang HH, et al. COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence [J]. FEBS J, 2020, 287(8): 1666-1680.
[13]	Liu TG, Sha KH, Zhang LG, et al. Protective effects of alpinetin on lipopolysaccharide/d-Galactosamine-induced liver injury through inhibiting inflammatory and oxidative responses [J]. Microb Pathog, 2019, 126: 239-244.
[14]	Qi J, Kim JW, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice [J]. Am J Pathol, 2020, 190(1): 68-81.
[15]	Li CX, Gao JG, Wan XY, et al. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-kappaB signaling pathways [J]. World J Gastroenterol, 2019, 25(34): 5120-5133.
[16]	Li X, Shi Z, Zhu Y, et al. Cyanidin-3-O-glucoside improves non-alcoholic fatty liver disease by promoting PINK1-mediated mitophagy in mice [J]. Br J Pharmacol, 2020, 177(15): 3591-3607.
[17]	Love S, Mudasir MA, Bhardwaj SC, et al. Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis [J]. Oncotarget, 2017, 8(69): 113403-113417.
[18]	Li G, Zhou F, Chen Y, et al. Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c [J]. Biomed Pharmacother, 2017, 89: 536-543.
[19]	Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH [J]. EMBO Mol Med, 2019, 11(2): e9302.
[20]	Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ-linking NAFLD and insulin resistance [J]. Endocr Rev, 2019, 40(5): 1367-1393.
[21]	Hwang SH, Wagner KM, Morisseau C, et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase [J]. J Med Chem, 2011, 54(8): 3037-3050.
[22]	Zhang YF, Sun CC, Duan JX, et al. A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress [J]. Biomed Pharmacother, 2020, 126: 109907.
[23]	Hye Khan MA, Hwang SH, Sharma A, et al. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat [J]. Prostaglandins Other Lipid Mediat, 2016, 125: 40-47.
[24]	Yang HH, Duan JX, Liu SK, et al. A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation [J]. Theranostics, 2020, 10(11): 4749-4761.
[25]	Castro RE, Diehl AM. Towards a definite mouse model of NAFLD [J]. J Hepatol, 2018, 69(2): 272-274.
[26]	Verbeek J, Lannoo M, Pirinen E, et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis [J]. Gut, 2015, 64(4): 673-683.
[27]	Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling [J]. Cell Mol Life Sci, 2015, 73(1): 79-94.
[28]	Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH [J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 349-364.
[29]	Sahin E, Bagci R, Bektur Aykanat NE, et al. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice [J]. J Food Biochem, 2020, 44(6): e13194.

COX-2/sEH双抑制剂PTUPB通过抑制内质网应激改善小鼠非酒精性脂肪性肝病

COX-2/sEH dual inhibitor PTUPB alleviates non-alcoholic fatty liver disease in mice by inhibiting endoplasmic reticulum stress

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 1

Metrics

本文评价

推荐阅读 0